Long-term treatment of multiple sclerosis with interferon-beta may be cost effective (Q34048580)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Long-term treatment of multiple sclerosis with interferon-beta may be cost effective	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

Europe PubMed Central

Long-term treatment of multiple sclerosis with interferon-beta may be cost effective (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

multiple sclerosis

0 references

author name string

Kendrick M

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Johnson KI

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

publication date

1 July 2000

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PharmacoEconomics

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

45-53

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Health care costs of veterans with multiple sclerosis: implications for the rehabilitation of MS. VA Multiple Sclerosis Rehabilitation Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11010603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://pubmed.ncbi.nlm.nih.gov/11010603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms of action of interferon-beta in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/11010603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A cost-utility analysis of interferon beta for multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/11010603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

https://pubmed.ncbi.nlm.nih.gov/11010603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/11010603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11010603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves

1 reference

https://pubmed.ncbi.nlm.nih.gov/11010603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://pubmed.ncbi.nlm.nih.gov/11010603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comprehensive assessment of the cost of multiple sclerosis in the United States

1 reference

https://pubmed.ncbi.nlm.nih.gov/11010603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic consequences of multiple sclerosis for Canadians

1 reference

https://pubmed.ncbi.nlm.nih.gov/11010603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://pubmed.ncbi.nlm.nih.gov/11010603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recent views on amyotrophic lateral sclerosis with emphasis on electrophysiological studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/11010603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic Evaluation of Multiple Sclerosis in the UK, Germany and France

1 reference

https://pubmed.ncbi.nlm.nih.gov/11010603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00019053-200018010-00005

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34048580&oldid=2196171509"